Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company was founded on March 29, 2004 and is headquartered in Carlsbad, CA.
Sector:
Health Technology
Industry:
Pharmaceuticals Other
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Qualigen Therapeutics Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Qualigen Therapeutics Inc market cap is $4.82M.
What is the 52-week high for Qualigen Therapeutics Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Qualigen Therapeutics Inc 52 week high is $10.45 as of September 22, 2025.
What is the 52-week low for Qualigen Therapeutics Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Qualigen Therapeutics Inc 52 week low is $1.61 as of September 22, 2025.
What is Qualigen Therapeutics Inc stock price today?
Qualigen Therapeutics Inc stock price today is $5.69.
What was Qualigen Therapeutics Inc stock price yesterday?
Qualigen Therapeutics Inc stock price yesterday was $2.84.
What is the PE ratio of Qualigen Therapeutics Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Qualigen Therapeutics Inc’s P/E ratio is -0.33.
What is the Price-to-Book ratio of Qualigen Therapeutics Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Qualigen Therapeutics Inc P/B ratio is -1.0456.
What is the 50-day moving average of Qualigen Therapeutics Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Qualigen Therapeutics Inc 50-day moving average is $2.25.